Our study aims to investigate the effect of a low-dose pioglitazone regimen on bone mineral density and bone formation-resorption markers in control and diabetic rats. Wistar rats were divided into 4 groups: non-diabetic controls, control rats receiving pioglitazone (3 mg/kg), streptozocin-treated diabetic rats (50 mg/kg), diabetic rats treated with pioglitazone (3 mg/kg). The duration of the e...

We aimed to compare the efficacy and safety of lobeglitazone and pioglitazone as add-ons to metformin in patients with type 2 diabetes. Patients who were inadequately controlled by metformin were randomized and treated once daily with either lobeglitazone (0.5 mg, n = 128) or pioglitazone (15 mg, n = 125) for 24 weeks, with a 28-week extension trial of lobeglitazone treatment in patients who co...

OBJECTIVE To compare coronary artery calcium (CAC) progression between 2 treatment groups, pioglitazone versus glimepiride. METHODS AND RESULTS The CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) study demonstrated that pioglitazone significantly decreased carotid intima-media thickness progression compared with glimepiride in patients with type 2 diabetes melli...

Objective(s): The aim of current study was to evaluate improving effects of pioglitazone as an agonist of peroxisome proliferator-activated receptor gamma (PPARγ), on brain-derived neurotrophic factor (BDNF) and cytokines as well as tissue oxidative damage criteria in the hippocampus in a rat model of lipopolysaccharide (LPS) induced memory impairment.<strong...

OBJECTIVE The goal of this study was to compare the effects of 2 doses of pioglitazone hydrochloride (a thiazolidinedione insulin sensitizer) with placebo on glycated hemoglobin (HbA(1c)), insulin sensitivity, and lipid profiles in patients with type 2 diabetes mellitus who had suboptimal glycemic control and mild dyslipidemia. METHODS Patients with type 2 diabetes mellitus (HbA(1c) >/=6.5% a...

AIMS/INTRODUCTION Low aerobic capacity is a strong and independent predictor of all-cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole-body aerobic capacity and skeletal muscle energy metabolism in MetS patients. MATERIALS AND METHODS A total of 14 male patients with MetS received oral pioglitazone 15 mg/day for 4 m...

Peroxisomeproliferator-activated receptorgamma(PPARg) is emergingasanewpharmacotherapeutic target for chronic pain.When oral (3e30mg/kg/day in chow for 7 wk) or twice-daily intraperitoneal (1e10mg/kg/ day for 2 wk) administration began before spared nerve injury (SNI), pioglitazone, a PPARg agonist, dosedependently prevented multiple behavioral signs of somatosensory hypersensitivity. The highe...

BACKGROUND: Diabetes mellitus (DM) type 2 is the most public chronic, metabolic illness whose prevalence quickly becoming high international. Insulin resistance, essential problem leads to development of DM 2, seen in about 90% patients. AIM: The study’s aim was compare efficacy three antidiabetic drugs on glycated hemoglobin. METHOD: A cross-sectional comparative study for newly diagnosed II d...

Thiazolidinediones are commonly used anti-diabetic drugs. Owing to the anti-inflammatory action of TZDs as a result of there action on the PPAR gamma receptor and a proposed action on the prostaglandins, these drugs can be tried in the acute exacerbations of COPD that are also commonly found among diabetic patients. An experimental study of one week was carried out at animal house of Army Medic...

OBJECTIVE Thiazolidinediones (TZDs), a class of insulin-sensitizing agents used clinically to treat type 2 diabetes, are also antiatherogenic. This study was designed to elucidate the relationship between the antiatherogenic and antidiabetic effects of pioglitazone, a TZD, in type 2 diabetic patients. RESEARCH DESIGN AND METHODS A total of 136 Japanese type 2 diabetic patients were included a...